

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203085Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA #: 203085
Drug Name: Stivarga® (Regorafenib)
Indication(s): Metastatic colorectal cancer
Applicant: Bayer HealthCare Pharmaceuticals
Date(s): Submission: 4/27/2012
PDUFA: 9/27/2012
Review Priority: Priority

Biometrics Division: Division of Biometrics V
Statistical Reviewer: Huanyu (Jade) Chen
Concurring Reviewers: Kun He, Team Leader
Rajeshwari Sridhara, Division Director

Medical Division: Division of Oncology Products 2
Clinical Team: Shan Pradhan, M.D., Clinical Reviewer for Efficacy
Kaushik Shastri, M.D., Clinical Reviewer for Safety
Steve Lemery, M.D., Team Leader
Patricia Keegen, M.D., Division Director
Project Manager: Monica Hughes

Keywords: stratified log-rank test, interim analysis, K-M curve, Cox regression

Table of Contents

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION	6
2.1	OVERVIEW.....	6
2.2	DATA SOURCES	6
3	STATISTICAL EVALUATION OF STUDY 14387.....	7
3.1	DATA AND ANALYSIS QUALITY	7
3.2	EVALUATION OF EFFICACY	7
3.2.1	OBJECTIVE.....	7
3.2.2	STUDY DESIGN	7
3.2.3	EFFICACY MEASURES	9
3.2.4	SAMPLE SIZE CONSIDERATIONS	10
3.2.5	INTERIM ANALYSIS.....	10
3.2.6	STATISTICAL METHODOLOGIES	11
3.2.7	APPLICANT’S RESULTS AND FDA STATISTICAL REVIEWER’S FINDINGS/ COMMENTS	11
3.2.7.1	PATIENT POPULATION AND DISPOSITION.....	11
3.2.7.2	BASELINE CHARACTERISTICS	12
3.2.7.3	PRIMARY EFFICACY ENDPOINT – OS.....	15
3.2.7.4	KEY SECONDARY ENDPOINT – PFS	16
3.2.7.5	KEY SECONDARY ENDPOINT – ORR	18
3.3	EVALUATION OF SAFETY	18
3.4	BENEFIT/RISK RATIO.....	18
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	19
4.1	OS SUBGROUP ANALYSIS.....	19
5	SUMMARY AND CONCLUSIONS	20
5.1	STATISTICAL ISSUES	20
5.2	COLLECTIVE EVIDENCE.....	20
5.3	CONCLUSIONS AND RECOMMENDATIONS	20
5.4	LABELING RECOMMENDATION	21

LIST OF TABLES

Table 1. Planned Stopping Criteria and Alpha Spending at the Interim and Final Analyses of OS	10
Table 2. Actual Stopping Criteria and Alpha Spending at the Interim and Final Analyses of OS	10
Table 3. Patient Population and Disposition (ITT).....	12
Table 4. Baseline Demographics Characteristics (ITT).....	12
Table 5. CRF Stratification Factors and Misclassifications at IVRS.....	13
Table 6 Baseline Disease Characteristics (ITT).....	14
Table 7. Prior Anti-Cancer Drugs.....	15
Table 8. OS Analyses (ITT).....	15
Table 9. Sensitivity Analyses for OS.....	15
Table 10. Number of Death by Planned Region.....	16
Table 11. FDA and Applicant’s PFS Analyses (ITT).....	17
Table 12. Sensitivity Analysis for PFS.....	18
Table 13. ORR Analyses (ITT)	18
Table 14. OS (Months) Subgroup Analysis.....	19

LIST OF FIGURES

Figure 1: Trial Schema	8
Figure 2. K-M Curves for OS	16
Figure 3. K-M Curves for PFS	17

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.